Stingray Therapeutics is a technology company.
Stingray Therapeutics has raised $280K across 2 funding rounds.
Stingray Therapeutics has raised $280K in total across 2 funding rounds.
Stingray Therapeutics has raised $280K in total across 2 funding rounds.
Stingray Therapeutics's investors include Autism Impact Fund, Mayfield, SOSV, Health Wildcatters.
Stingray Therapeutics is a clinical-stage biotechnology company developing next-generation immune therapies targeting innate immunity to combat cancer.[1][2][3][5] It focuses on potent, selective small molecule inhibitors of ENPP1, the direct negative regulator of the STING pathway, which activates innate immune responses without over-activating the system or risking autoimmune issues seen in competitors.[2][3][4] The company serves oncology patients, addressing limitations of first-generation adaptive immunity therapies like checkpoint inhibitors, which face increasing resistance and fail to treat many tumors, including pediatric cancers like medulloblastoma.[1][4] Its lead program shows promise as a single agent and in combinations with radiation, checkpoint inhibitors, PARP inhibitors, CAR-T/NK therapies, targeted therapies, and chemotherapy, with an IND filing planned for March 2023 and 2 clinical trials underway.[1][2][3]
Headquartered in Houston, TX (with mentions of Salt Lake City, UT), Stingray has <25 employees and revenue under $5 million, positioning it as an early-to-mid-stage player with grants/awards supporting growth.[3][5]
Stingray Therapeutics emerged to bridge a gap in immune oncology by targeting innate immunity, complementing adaptive therapies that dominate the field.[1][4] Founded around 2021 (based on earliest records), it is led by CEO Jonathan (Jon) Northrup, who emphasizes a "revolutionary approach" enabling the full immune system to fight cancer.[1][5] The idea stemmed from recognizing that current immunotherapies overlook innate immunity's synergistic role, leading to resistance in tumors unresponsive to T-cell or checkpoint modulation.[1][4] Early traction includes promising preliminary data on ENPP1 inhibitors, 2 clinical trials in neoplasms, 1 patent-related activity, and plans for IND submission in March 2023, alongside grants and awards.[1][2][5] Pivotal moments involve differentiating from failed first-generation STING agonists (e.g., cyclic dinucleotides requiring tumor injections or systemic risks).[3]
Stingray rides the innate immunity wave in oncology, shifting from adaptive-only therapies amid rising resistance to checkpoint inhibitors and PD-1/PD-L1 drugs.[1][4] Timing aligns with STING pathway advances post-2020s, where ENPP1 emerges as a key regulator, enabling safer agonists amid failures of earlier approaches.[2][3] Market forces favor it: global immuno-oncology exceeds $100B, with innate immunity combos projected to capture share as ~70% of patients resist adaptive monotherapy; pediatric and cold tumor needs amplify urgency.[1][4] It influences the ecosystem by pioneering oral innate modulators, potentially boosting combo regimens and expanding responsive tumors, fostering synergies with Big Pharma cell therapies and radiation tech.
Stingray's ENPP1 inhibitors position it for breakthrough combos unlocking innate-adaptive synergy, with IND readout and Phase 1/2 data post-2023 driving partnerships or acquisition by majors like Merck or Novartis.[2][3][5] Trends like AI-optimized immuno combos and bispecifics will amplify its role, especially in resistant/pediatric oncology. Influence may evolve from niche innovator to ecosystem enabler, delivering durable cures where adaptive therapies falter—revitalizing immune oncology's next frontier.[1][4]
Stingray Therapeutics has raised $280K across 2 funding rounds. Most recently, it raised $250K Seed in June 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2019 | $250K Seed | Autism Impact Fund, Mayfield, SOSV | |
| Sep 1, 2018 | $30K Seed | Health Wildcatters |